Treats relapsed or refractory acute myeloid leukemia (AML) with an isocitrate…. Sold as Idhifa. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Enasidenib Mesylate (sold as Idhifa), first approved Aug 1, 2017, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Idhifa | Part D | $258M | +40% | 1,264 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · National Cancer Institute (NCI) | Phase 2 | Recruiting | Oct 3, 2022 |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 MutationRecurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · Children's Oncology Group | Phase 2 | Active, not recruiting | Dec 18, 2019 |
| CPX-351 Plus Enasidenib for Relapsed AMLRecurrent Acute Myeloid Leukemia · Jonsson Comprehensive Cancer Center | Phase 2 | Active, not recruiting | Jan 31, 2019 |
| Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationAcute Myeloid Leukemia · City of Hope Medical Center | Phase 2 | Active, not recruiting | Nov 2, 2018 |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationAcute Bilineal Leukemia, Acute Biphenotypic Leukemia · M.D. Anderson Cancer Center | Phase 2 | Recruiting | Sep 25, 2018 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 1, 2017 | IdhifaNDA 209606 · New molecular entity | Bristol Myers Squibb | 6 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA